Molecular mechanisms of sglt2 inhibitor on cardiorenal protection

Yi Chou Hou, Cai Mei Zheng, Tzung Hai Yen, Kuo Cheng Lu

Research output: Contribution to journalReview articlepeer-review

35 Citations (Scopus)


The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre-and post-glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.

Original languageEnglish
Article number7833
Pages (from-to)1-25
Number of pages25
JournalInternational journal of molecular sciences
Issue number21
Publication statusPublished - Nov 1 2020


  • Cardiovascular disease
  • Chronic kidney disease
  • Diabetes mellitus
  • SGLT2

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Molecular mechanisms of sglt2 inhibitor on cardiorenal protection'. Together they form a unique fingerprint.

Cite this